Real-world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis.
Bryrup T, Faurholt-Jepsen D, Pressler T, Henriksen EH, Leo-Hansen C, Nielsen BU, Højte C, Mathiesen IHM, Katzenstein TL, Jeppesen M, Jensen-Fangel S, Olesen HV, Skov M, Qvist T, Olsen MF; TransformCF Study Group.
Bryrup T, et al. Among authors: hojte c.
APMIS. 2024 Oct;132(10):728-733. doi: 10.1111/apm.13453. Epub 2024 Aug 2.
APMIS. 2024.
PMID: 39092470